Zobrazeno 1 - 10
of 25
pro vyhledávání: '"A. Nasser Khan"'
Autor:
Andrea Rubbert-Roth, Koji Kato, Boulos Haraoui, Maureen Rischmueller, Yanxi Liu, Nasser Khan, Heidi S. Camp, Ricardo M. Xavier
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 5, Pp 1197-1215 (2024)
Abstract Introduction The safety and efficacy of upadacitinib 15 mg (UPA15) through week 216 was evaluated in patients with rheumatoid arthritis (RA) from the long-term extension (LTE) of the phase 3 SELECT-CHOICE study. Methods Patients with RA refr
Externí odkaz:
https://doaj.org/article/d313932347fc4677b9fb4fe93f411d0d
Autor:
Ronald van Vollenhoven, Vibeke Strand, Tsutomu Takeuchi, Nilmo Chávez, Pablo Mannucci Walter, Atul Singhal, Jerzy Swierkot, Nasser Khan, Xianwei Bu, Yihan Li, Sara K. Penn, Heidi S. Camp, Jacob Aelion
Publikováno v:
Arthritis Research & Therapy, Vol 26, Iss 1, Pp 1-15 (2024)
Abstract Background To evaluate the efficacy and safety of upadacitinib monotherapy versus methotrexate (MTX) monotherapy over 5 years among MTX-naïve patients with moderately to severely active rheumatoid arthritis (RA) in the long-term extension (
Externí odkaz:
https://doaj.org/article/d96238b03a104e99a640cf8bd22d5e92
Autor:
Roy Fleischmann, Ricardo Blanco, Filip Van den Bosch, Louis Bessette, Yanna Song, Sara K. Penn, Erin McDearmon-Blondell, Nasser Khan, Kelly Chan, Eduardo Mysler
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 3, Pp 599-615 (2024)
Abstract Introduction This study aimed to describe the long-term efficacy and safety of upadacitinib and adalimumab through 228 weeks following immediate switch to the alternate therapy with a different mechanism of action (MoA) in patients with rheu
Externí odkaz:
https://doaj.org/article/bda276920acf4632bf961e69f50d248a
Autor:
Roy Fleischmann, Stephen Hall, Bernard Combe, Andrea Rubbert-Roth, Christina Charles-Schoeman, Nasser Khan, Heidi S Camp, Sebastian Meerwein, Kyle M Carter
Publikováno v:
RMD Open, Vol 10, Iss 3 (2024)
Objective To evaluate the efficacy and safety of upadacitinib over 5 years among patients with rheumatoid arthritis (RA) in a long-term extension (LTE) of the SELECT-BEYOND phase 3 trial.Methods Patients refractory to ≥1 biological disease-modifyin
Externí odkaz:
https://doaj.org/article/76db6d5729924754958a446387d0a992
Autor:
Christina Charles-Schoeman, Jon T. Giles, Nancy E. Lane, Ernest Choy, Daniel E. Furst, Jiří Vencovský, Anthony G. Wilson, Gerd R. Burmester, Derek Coombs, Sara K. Penn, Nasser Khan, Jillian B. Yee, Kassim Rahawi, Iain B. McInnes
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 1, Pp 157-175 (2024)
Abstract Introduction Upadacitinib (UPA) is a Janus kinase inhibitor that has demonstrated efficacy in moderate-to-severe rheumatoid arthritis (RA) with an acceptable safety profile. We investigated laboratory parameter changes in UPA RA clinical tri
Externí odkaz:
https://doaj.org/article/7848bcb7d51248bd8d20a0519b6de718
Autor:
Roy Fleischmann, Patrick Durez, Eduardo Mysler, Louis Bessette, Yihan Li, Nasser Khan, Charles G Peterfy, Jerzy Swierkot, Xianwei Bu, Sara K Penn
Publikováno v:
RMD Open, Vol 10, Iss 2 (2024)
Objectives To assess the safety and efficacy of upadacitinib versus adalimumab from SELECT-COMPARE over 5 years.Methods Patients with rheumatoid arthritis and inadequate response to methotrexate were randomised to receive upadacitinib 15 mg once dail
Externí odkaz:
https://doaj.org/article/0ddc11c0f0aa4feea539213725b8018e
Autor:
Alan Kivitz, Alvin F. Wells, Juan I. Vargas, Herbert S. B. Baraf, Maureen Rischmueller, Justin Klaff, Nasser Khan, Yihan Li, Kyle Carter, Alan Friedman, Patrick Durez
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 4, Pp 901-915 (2023)
Abstract Introduction Upadacitinib (UPA) is an oral, selective Janus kinase inhibitor that has demonstrated favorable efficacy with an acceptable safety profile across a global, phase 3 program in rheumatoid arthritis (RA). This phase 2 open-label ex
Externí odkaz:
https://doaj.org/article/9b7fbbcc263c40338f0904ba90e40d30
Autor:
Peter Nash, Iain B McInnes, Ernest Choy, Jeffrey R Curtis, Eduardo Mysler, Christina Charles-Schoeman, Nasser Khan, Kunihiro Yamaoka, Ralph Lippe, Hannah Palac, Anna K Shmagel, Jessica Suboticki
Publikováno v:
RMD Open, Vol 9, Iss 4 (2023)
Objectives To provide an integrated analysis of major adverse cardiovascular events (MACEs) and events of venous thromboembolism (VTE) and associated risk factors across rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis
Externí odkaz:
https://doaj.org/article/96e4777199e341a9a15e8df4409cc6f2
Autor:
Roy Fleischmann, Patrick Durez, Yoshiya Tanaka, Eduardo Mysler, Louis Bessette, Yihan Li, In-Ho Song, Nasser Khan, Charles G Peterfy, Jerzy Swierkot, Xianwei Bu
Publikováno v:
RMD Open, Vol 8, Iss 1 (2022)
Externí odkaz:
https://doaj.org/article/41dd43ffef0448a1ad8b48311ffdf715
Autor:
Alan Kivitz, Alvin F Wells, Juan I Vargas, Herbert S B Baraf, Maureen Rischmueller, Justin Klaff, Nasser Khan, Yihan Li, Kyle Carter, Alan Friedman, Patrick Durez
Publikováno v:
Rheumatology. 62
Background/Aims Upadacitinib (UPA) was previously evaluated in two Phase 2, randomized, controlled trials (RCTs) in patients (pts) with rheumatoid arthritis (RA) and inadequate response to tumor necrosis factor inhibitors (BALANCE-1) or methotrexate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7d58852740a55f7b26ea244ff599f039
https://doi.org/10.1093/rheumatology/kead104.169
https://doi.org/10.1093/rheumatology/kead104.169